BOOK BY 23 AUGUST TO SAVE UP TO £700

4 – 6 December 2019 | London, UK
tumour-models.com

8th Annual
PREDiCT: TUMOUR MODELS LONDON

Empower Your Model Selection Strategy to Enhance Preclinical Candidate Success

Join the Community of Preclinical Experts to Accelerate the Development of Your Therapeutic Candidates

Expert Speakers Include:

Sukhvinder Sidhu
Global Head of Pharmacology
Sanofi

Sara Colombetti
Head of Global Oncology Discovery Pharmacology & Group Leader
Roche Innovation Center

James Yates
Principal Scientist
AstraZeneca

Paul McSheehy
Senior Scientist & Leader, Cancer Biology *In Vivo* & Translational Science Oncology
Basilea Pharmaceutica

Anita Seshire
Head of Laboratory Cellular Pharmacology & Translational Innovation Platform Oncology
Merck Healthcare KGaA

Lead Partner:
CrownBio
CONNECTING SCIENCE TO PATIENTS

Programme Partners:
The Jackson Laboratory
inVotion
WHICH MOLECULE WILL STAND OUT

Spotlight Partners:
genOway
Bioresearch
hera BioLabs
mAbs
ProQinase
REACTION BIOLOGY CORP.

Exhibitors:
VIVOPHARM
A CGI COMPANY
CHAMPIONS ONCOLOGY
repositive

Tel: +44 (0)20 3141 8700 **Email:** info@hansonwade.com
Tumour Models @Predict_models

hansonwade

8th Annual PREDiCT: Tumour Models London Summit

The PREDiCT: Tumour Models London Summit is back!

This year, we are revealing the latest progress showcasing how preclinical tumour models support the immunotherapy revolution to develop successful therapeutic candidates.

With over **20 case studies**, this is your opportunity to hear from the likes of **AstraZeneca**, **Basilea Pharmaceutica** and **Sanofi** showcasing their validation techniques to guide your model selection strategy.

Join us alongside **100+ leading experts** to gain insight into tackling tumour resistance, immune-tumour cell targeting and discover validation techniques of the latest models. Learn how to **accelerate your therapeutic outcomes for greater preclinical candidate success**.

We look forward to welcoming you in London!

What previous PREDiCT Tumour Models London attendees have to say

"This was an excellent conference and an excellent forum to network with others working at the cutting edge of cancer research"
Anne Cheasty, Senior Principal Scientist, Cancer Research Technology

"The meeting was informative, a good size and with good networking opportunities"
Daniel Hynes, Preclinical Manager, e-Therapeutics

"It was a truly inspiring conference with great scientific discussions and networking. I gained insight in addition to the publicly available knowledge"
Dr. Anita Seshire, Head of Laboratory, Merck Healthcare KGaA

Cutting Edge Strategies Revealed by Industry Leaders

Roche

***In Vivo* Profiling of Cancer Immunotherapies**
Case studies exploring how preclinical data **can predict clinical outcomes**

SANOFI

Evaluating Humanised Models
Insight into the effects of **different immunotherapies** and their **outcomes** across various **humanised mouse models**

MERCK

Utilising the 3D Advantage
Determine how to apply stem cells to study the **interactions of microenvironment**

GUSTAVE ROUSSY CANCER CAMPUS GRAND PARIS

Tackling Tumour Resistance
Learn how to model acquired **patient-derived resistance** utilising organoids and PDX models

MedImmune

Proof of Concept with I/O Therapeutics
Select the **appropriate syngeneic models** with proof of principle with I/O therapeutics

"The agenda was well balanced with opportunities to engage in discussion. The networking sessions were great." **Gilead, PREDiCT Series Attendee**

Tel: +44 (0)20 3141 8700 Email: info@hansonwade.com
www.tumour-models.com Tumour Models @Predict_models
hansonwade

Your 20+ Expert Speakers

Sukhvinder Sidhu
Global Head of Pharmacology
Sanofi

Neta Moskovits
Head of The Translational Cancer Research Lab
Rabin Medical Center

Anita Seshire
Head of Laboratory Cellular Pharmacology & Translational Innovation Platform Oncology
Merck Healthcare KGaA

Roberto Speck
Principal Investigator
University of Zurich

Jennifer Walker
Principal Scientist
MedImmune

Sara Colombetti
Head of Global Oncology Discovery Pharmacology & Group Leader
Roche Innovation Center

Ludovic Bigot
Project Manager
Institut Gustave Roussy

Olivia Harris
Post-Doctoral Fellow
MedImmune

Herve Luche
Director, Scientific Immunophenotyping Unit
CIPHE - Centre D'ImmunophENomique

Niina Veitonmaki
Director, *In Vivo* Immune-Oncology & Head of *In Vivo* Core
Molecular Partners AG

Paul McSheehy
Senior Scientist & Leader, Cancer Biology *In Vivo* & Translational Science Oncology
Basilea Pharmaceutica

James Yates
Principal Scientist
AstraZeneca

Rajendra Kumari
Global Head of Scientific Communications
Crown Bioscience

Ralph Gareus
Director Business Development Europe
The Jackson Laboratory

Jean Viallet
Chief Executive Officer
INOVOTION

Maryland Franklin
Vice President Scientific Development
MI Bioresearch

Tseten Jamling
Vice President of Research & Development
Hera Labs Inc.

Kader Thiam
Vice President of Transgenic Technologies
genOway

Gabri Van Der Pluijm
Head of Urology Research Laboratory
Leiden University

Hitesh Mistry
Clinical Pharmacometrics, Biostatistics, Data Science Senior Research Fellow
University of Manchester

Tao You
Pharmacokinetic & Pharmacodynamics Modeller & Data Scientist
Beyond Consulting Ltd

Krzysztof Wicher
Director, Pharmacology & Translational Sciences
Kymab

Christine Engeland
Cancer Researcher
National Center for Tumor Diseases

John Prime
Principal Consultant
OncoBioinformatics Consulting

Workshop Day
Wednesday 4 December

Workshop A
9.00am - 12.00pm

Utilising Bioinformatics to Advance Preclinical Decision Making

This short course will introduce how translational PK/PD modelling for chemotherapy and cell-directed targeted therapy can be used to relate preclinical data with clinical response.

Learning Outcomes:

- Learn how to define the quantitative relationship between preclinical efficacy and clinical activity for I/O therapeutics
- Discuss the possibility to set minimum preclinical efficacy criteria to qualify a novel treatment for clinical success
- Apply translational modelling framework insights to best support drug projects

Workshop Leader

Tao You
Pharmacokinetic & Pharmacodynamics Modeller & Data Scientist
Beyond Consulting Ltd

John Prime
Principal Consultant
OncoBioinformatics Consulting

Workshop B
1.00pm- 4.00pm

Validation Techniques Using Humanised Mouse Models

This workshop will explore the different strategies of immune system humanisation in mice as well as to review challenges, insights and future directions for mouse and humanised models within oncology.

Learning Outcomes:

- What is the state of the art of humanised mouse models?
- What is the pre-requisite that a humanised mouse model is a good model for studying cancer?
- Do current humanised mouse models satisfy the need for cancer research?

Workshop Leader

Roberto Speck
Principal Investigator
University of Zurich

"The conference was very informative. I especially enjoyed the pre-conference workshops. I learned a great deal about the pros and cons of the models used for immunotherapy"

Senior Director, Immunology, Calvert Laboratories Inc., PREDiCT Series Attendee

Conference Day One
Thursday 5 December

7.30 **Welcome Coffee & Registration**

8.20 **Chair's Opening Remarks**

Utilise the Advantages of Specific Model Type to Your Research Objectives

Jennifer Walker
Principal Scientist
MedImmune

8.30 **Preclinical Modelling of Immuno-Oncology Therapies**

- Selection of appropriate syngeneic models, based on in-depth cellular and molecular characterisation of the immune infiltrate)
- Demonstration of immune memory and abscopal effects in syngeneic models
- Use of short, proof-of-principle models to triage immuno-oncology (I/O) drug combinations
- Adapting PDX study design to inform on biomarker identification and patient stratification

Neta Moskovits
Head of The Translational Cancer Research Lab
Rabin Medical Center

9.00 **Unique PDX Models to Advance Liquid-Biopsy Research & Immunotherapy**

- Learn how applying CTC-derived PDX provides clinically relevant information on metastasis formation
- Autologous humanised mice model for I/O studies: same-patient immune system and tumour tissue in one mice
- Using PDX models to develop novel combination therapies

Rajendra Kumari
Global Head of Scientific Communications
Crown Bioscience

9.30 **Tumour Microenvironment, Heterogeneity & Clinically Relevant Models**

- Addressing the demand for clinically relevant models to understand disease progression and identifying responsive patient populations
- Developing 3D systems and PDX modelling to enhance translational success
- Adopting the right models across oncology therapeutics

Sukhvinder Sidhu
Global Head of Pharmacology
Sanofi

10.00 **Assessment of Different Humanised Mouse Models for the Evaluation of Cancer Immunotherapies**

- Comparison of humanisation of immune system with huCD34+ HSC in different strains of immune-deficient mice (NSG, NSG SGM3, NOG & NOG-EXL)
- Evaluation of humanised PBMC mouse models
- Insight into the response of immunotherapies in different humanised mouse models with tumours (PDX and CDX)

10.30 **Speed Networking**

Join our quick-fire session and connect with 100+ preclinical experts

11.15 **Morning Refreshments**

Ralph Gareus
Director Business Development Europe
The Jackson Laboratory

11.45 **Sophisticated Humanised Mouse Models to Investigate the Mechanisms of Immunotherapy**

- Understanding how animal models can provide accurate *in vivo* conditions to mimic the natural tumour environment
- Presenting data on how these humanised models in combination with patient-derived xenografts can be used to study immune checkpoint blockade
- Providing an overview of new transgenic host strains in development, which will allow improved engraftment of human immune systems

12.15 Panel Discussion – Industry Insight: How to Utilise Complimentary Models to Drive Drug Discovery Development

- Insights across the model continuum to validate and optimise drug candidates to improve clinical outcomes
- What are the advantages and limitations for each model?
- What needs to be achieved to increase reproducibility and standardisation across the industry?

Sukhvinder Sidhu
Global Head of Pharmacology
Sanofi

Anita Seshire
Head of Laboratory Cellular Pharmacology & Translational Innovation Platform Oncology
Merck Healthcare KGaA

Ralph Gareus
Director Business Development Europe
The Jackson Laboratory

Paul McSheehy
Senior Scientist & Leader, Cancer Biology *In Vivo* & Translational Science Oncology
Basilea Pharmaceutica

Rajendra Kumari
Global Head of Scientific Communications
Crown Bioscience

13.00 Lunch and Networking

Apply Complex 3D Models to Support *In Vivo* Modelling Outcomes

Anita Seshire
Head of Laboratory Cellular Pharmacology & Translational Innovation Platform Oncology
Merck Healthcare KGaA

14.00 3D Cancer Stem Cell Models to Study Microenvironment Interactions and Tumour Plasticity

- Insight into the development of primary 3D cell cultures from patient material
- Addition of monocytes or fibroblasts to identify a potential trophic role
- Transplantation of multicellular spheres to create tumours with microenvironments (TME) and enable the exploration of the influence of the TME on stemness

Jean Viallet
Chief Executive Officer
INOVOTION

14.30 Early *In Vivo* Identification of Low Value Molecules

- How to use INOVOTION technology to open new perspectives of *in vivo* screening in oncology and immune-oncology
- Why chick embryo model has several advantages for drug discovery of anticancer treatments
- Chick embryo model fills the gap between *in vitro* and mouse model, but is it possible to predict mouse data from chick embryo results?

Krzysztof Wicher
Director, Pharmacology & Translational Sciences
Kymab

15.00 Re-Balancing the Suppressive Tumour Environment – Restoring an Effective Immune Response

- Suppressive tumour micro-environments arising from a complex interplay between the innate: the adaptive immune system, the stroma and the mutational context of the tumour itself
- How to identify fully human monoclonal antibodies and develop treatments that address key aspects of tumour immune-suppression
- Insight into different *in vitro* and *in vivo* modelling capabilities to dissect the activity and MoA of lead molecules supporting critical questions about their applicability to further development

15.30 Q/A Session:
Interactive session to uncover more from the latest case studies

- How can 3D models improve the clinical relevancy of *in vivo* models to drive preclinical success?
- What do checkpoint inhibitors reveal about the complex interaction between tumour, microenvironment and immune system?
- How can these therapies be combined to model the active immune system?

15.45 Afternoon Break & Networking

Paul McSheehy
Senior Scientist & Leader, Cancer Biology *In Vivo* & Translational Science Oncology
Basilea Pharmaceutica

16.15 Preclinical Profiling of Derazantinib (BAL087), an FGF-R Inhibitor Currently in Phase-2 Clinical Trials

- Insight into kinase profile and *in vitro* activity of BAL087
- Incorporating PK-PD modelling to establish the candidate profile
- Monitoring activity in PDX-models, future development and challenges

Tseten Jamling
Vice President of Research & Development
Hera Labs Inc.

16.45 Expertise Insight from Hera Biolabs

17.00 Roundtable Discussion

Debate, learn and network alongside 100+ preclinical experts over the following leading issues of the preclinical oncology landscape:

1. Cell Handling, Guidelines & Donor Differential Donor Response

- Increasing standardisation in cell handling protocol to enhance reproducibility
- The challenge of tissue heterogeneity in modelling specific immune-responses from patient derived samples

2. Investigating the Potential of Utilising the Microbiome

- Genomic analysis of human samples to differentiate the benign and malignant disease state
- The role of the microbiome in tumour response to therapy
- Incorporating bacteria administration to increase preclinical success of *in vivo* models

3. Latest Strategies to Model Tumour Resistance

- Industry approaches to overcoming solid tumour resistance
- What are the strengths of the validation of modelling patient level responses to resistance?

4. Applying Complex 3D Models to Increase *In Vivo* Efficacy

- The advantages of combining organoids with *in vivo* models to increase the accuracy of candidate screening
- What are the limitations and advantages of understanding therapy resistance and tumour development?

17.45 Moderator Feedback

An overview of key discussion points and takeaways from the roundtable discussion

18.15 Chair's Closing Remarks

Kindly Hosted By:
CrownBio
CONNECTING SCIENCE TO PATIENTS

18.30 Evening Drinks Reception & Poster Session

Continue to build your network during this interactive session, in which the latest data on *in vivo* oncology modelling, efficacy studies and target validation will be presented

"The depth of the discussion, and opportunities to hear perspectives from those leading the industry on developing models made this an exceptionally valuable meeting - I look forward to participating in future summits."

Barbara Joyce-Shaikh, Merck, PREDiCT Series Attendee

Conference Day Two
Friday 6 December

8.00 **Morning Refreshments**

8.15 **Chair's Opening Remarks**

Use Novel Immunology Co-Targets to Drive Preclinical Success

Niina Veitonmaki
Director, Oncology & Head of *in Vivo* Core
Molecular Partners AG

8.30 **Preclinical Animal Models of DARPin Molecule PD Assessment**

- Utilising animal models to explore compound activity, mechanism of action and biomarker discovery
- Hurtles and opportunities of animal models, can they translate clinically?

Sara Colombetti
Head of Global Oncology Discovery Pharmacology & Group Leader
Roche Innovation Center

9.00 **Sharpening the Preclinical Insight: Innovative Models with Increased Clinical Relevance & Predictive Value for *In Vivo* Profiling of Cancer Immunotherapies**

- Developing pre-clinical models for cancer immunotherapy: a complex task
- Moving towards "high bar" preclinical tumour models - immuno-competent and humanised mouse models
- *In vivo* profiling of cancer immuno-therapies in clinically relevant tumour models: how preclinical data can predict clinical outcome

Maryland Franklin
Vice President Scientific Development
MI Bioresearch

9.30 **Syngeneic Models of Breast Cancer: Effects of Immune Modulatory Agents in Classically "Cold" Tumours**

- How to select between murine breast cancer models
- Preclinical immunotherapy approaches in murine breast cancer models

Olivia Harris
Post-Doctoral Fellow
MedImmune

9.45 **Seeing is Believing: Making Sense of the Tumour Microenvironment Spatial Organisation Using Patient Derived Tissue Slices**

- Outlining the advantages of applying 3D patient-derived *ex vivo* culture systems
- What are current limitations and future directions?

10.15 **Q/A Session**

- What are the greatest challenges facing targeted therapeutics of the tumour microenvironment?
- The issue of balancing immune response with toxicity profiles

10.30 **Morning Coffee & Networking Break**

Increase Translational Efficacy of Preclinical Candidates

Herve Luche
Director, Scientific Immunophenotyping Unit
CIPHE - Centre D'ImmunophENomique

11.00 **Immuno-Profiling of Murine Tumour Models to Improve Translational Prediction for Immune-Based Therapeutics**

- Tumour cell line editing by CrispR/Cas9 B6 and BalbC Syngenics, GEMs
- Standardised experimental approach to manage cohorts of up to 48 animals for multi-variate multi-group studies
- Immuno-profiling of multiple tissues by flow, spectral or mass cytometry
- Advanced data analysis methodologies to identify which cell subsets correlate to a treatment candidate

Kader Thiam
Vice President of Transgenic Technologies
genOway

11.30 **Immune Checkpoints; Humanised Preclinical Models for Biologics' Efficacy & MoA**

- Exploring how model design impacts the physiological relevance and the predictability of preclinical outcomes

Gabri Van Der Pluijm
Head of Urology Research Laboratory
Leiden University

11.45 'Near-Patient' Models for the Assessment of Individualised Drug Responses in Urological Malignancies

- Translational benefits and limitations of patient-derived *ex-vivo* cultured tumour slices
- Can heterotypic tumour-TME interactions, e.g. heterotypic tumour-immune cell interactions, be studied?

12.15 Lunch & Networking

Modulate the Immune System with Oncolytic Viruses

Christine Engeland
Cancer Researcher
National Center for Tumor Diseases

13.15 Complementary Models to study Oncolytic Virus Immunotherapy

- Challenges in identifying appropriate models to Study mechanisms of oncolytic immunotherapy
- Enabling bench-to-bedside-and-back approaches

Overcome Tumour Resistance with Novel Targets

Hitesh Mistry
Clinical Pharmacometrics, Biostatistics, Data Science Senior Research Fellow
University of Manchester

13.45 Curious Preclinical-Clinical Correlations of Marketed IO Therapies

- Discuss the preclinical pharmacology data supporting registration
- Explore the design and data collected in the Phase 1 studies
- Highlight some direct correlations between preclinical data and Phase 1 studies that could be used for dose selection and justification

James Yates
Principal Scientist
AstraZeneca

14.15 Mind the Translational Gap - Improving Preclinical Outcomes through PK PD Modelling

- A review of different animal cancer model available and how they are informative for modelling
- The evidence for preclinical to clinical translation
- The translational gaps that exist and how modelling and simulation can be used to bridge these

Ludovic Bigot
Project Manager
Institut Gustave Roussy

14.45 MATCH-R, Development of Preclinical Models from Patients with Acquired Resistance to Targeted Therapy

- Highlighting the development of a panel of PDX models and organoids derived from biopsies collected at the stage of acquired resistance
- Demonstrating how these preclinical models will be used to improve knowledge on the mechanisms underlying resistance to treatment
- Exploring the impact on evaluating response to new treatments

15.15 Q/A Session

- Interactive speaker panel insight
- How to identify novel mechanisms to increase the success of combination therapeutics?
- How can guidelines assist in handling patient tumour samples to produce more disease-relevant models?

15.30 Chair's Closing Remarks

2019 CONFIRMED PARTNERS

The ***PREDiCT: Tumour Models London Summit*** partners with leading model providers, imaging specialists, CRO's and tissue providers.

This annual meeting is your opportunity to **develop your growth plans** by connecting you with senior preclinical oncology experts.

As a community, we are dedicated to driving progress by building **effective business relationships** across the immuno-oncology modelling industry.

Lead Partner

CrownBio
CONNECTING SCIENCE TO PATIENTS

Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, CrownBio enables clients to deliver superior clinical candidates and accelerate drug development programs. CrownBio also provides preclinical immunotherapy research platforms supporting the successful transition of immunotherapeutics from the lab into the clinic.

www.crownbio.com

Program Partner

inovotion
WHICH MOLECULE WILL STAND OUT

INOVOTION is a Contract Research Laboratory implementing a unique approach to *in vivo* evaluation for anticancer drug discovery. Our cutting-edge proprietary technology provides early analysis of your compounds before the classical preclinical stage. By eliminating low-value molecules early, INOVOTION accelerates your drug discovery process and significantly reduces its costs. INOVOTION has developed a unique technology dedicated to early *in vivo* EFFICACY and TOXICITY evaluation of anti-cancer drugs.

www.inovotion.com

Program Partner

The Jackson Laboratory

The Jackson Laboratory is a leading provider of cancer mouse models and *in vivo* oncology services and a National Cancer Institute designated Cancer Center. Drawing on decades of research experience we provide capabilities around model selection, husbandry and customisable oncology studies to help clients and researchers evaluate novel anti-cancer therapies. Our diverse oncology study protocols range from traditional xenograft services to PDX cancer models and advanced humanised mouse models for immuno-oncology drug development.

www.jax.org

Spotlight Partner

MI Bioresearch
Advancing Your Preclinical Oncology

MI Bioresearch (MI), a preclinical oncology service provider, offers *in vitro* services, oncology pharmacology, *in vivo* imaging, and focal radiation to support research programs. Our team explores the effects of your drugs and biologics using both human and syngeneic models and multi-modality imaging systems. MI provides you with decision-driving data to help advance your drug candidate toward the next cancer research breakthrough. One Focus. One Purpose. Oncology Research.

www.mibioresearch.com

Spotlight Partner

hera BioLabs

Hera Biolabs, Inc., is an innovative pre-clinical CRO utilising cutting edge gene-editing technologies to create novel *in vivo* models for oncology. Given our mission to accelerate cancer research and drug development, we focus upon rat models to deliver translationally relevant, high-quality results using proprietary technologies. Our first SRG model is the OncoRat®, which is uniquely suited for xenograft studies given its excellent tumour take-rates and ability to deliver masses 10x that of mouse models in half the time – all without the increased risk of genetic drift from multiple passages as observed in mice.

www.herabiolabs.com

Spotlight Partner

ProQinase GmbH was founded in 2001 as a subsidiary of the Tumor Biology Center Freiburg. This cancer center combined excellent research with exceptional patient care under one roof. Initially, ProQinase was established in order to support funding of the Tumor Biology Center´s in-house anti-cancer drug development by marketing research tools and test systems. Today, ProQinase is a leading contract research organization (CRO) for drug discovery in oncology. In February 2019 ProQinase was purchased by Reaction Biology Corporation located in Malvern, PA. RBC is a leader in early stage drug-discovery services, with a heavy focus on kinase and epigenetic drug targets for both biochemical and cell-based assays. The combination of RBC and ProQinase will create the world's leading kinase drug discovery company, with a diverse offering and operations in Europe and the United States.

www.proqinase.com

Spotlight Partner

Mi-mAbs is an innovative integrated immunotechnology center designed to accelerate the development of new immunotherapy antibodies against cancer and inflammatory diseases. Open to the best targets of academic and industrial research, MI-mAbs determines their expression profile, generates antibodies and validates them.

MI-mAbs, a multi-disciplinary team, involving experts in hybridoma, in molecular biology, biochemistry, immunochemistry , anatomopathology and in vitro/ in vivoimmunopharmacology has an objective to be the 1st integrated platform that generates and validates therapeutic antibodies in Cancerology and Inflammation. MI-mAbs contracts with research institutions, public technology transfer offices, or biotech companies.

www.mimabs.org

Spotlight Partner

GenOway specialises in genetic designs to serve genetically modified (GM) mice, rat and cell lines of highest standards for academic and bio-pharmaceutical research, and has created more than 2000 GM models, while serving clients in:

- 28 countries worldwide
- 380 academic institutions and 13 EU projects
- 170 Life Sciences companies
- 15 of the Top 20 pharma

www.genoway.com

Exhibitor

VIVOPHARM, a CGI company (NASDAQ:CGIX), is a successful and fast-growing precision contract research organisation (CRO) providing integrated preclinical services from bench to bedside worldwide. We use our experience and expertise to assist in the planning of and conducting tailored studies, from discovery stages through to clinical.

www.vivopharm.com.au

Exhibitor

Champions Oncology was founded by renowned specialists in the field of cancer diagnosis, treatment, and research. The Champions Oncology team is comprised of seasoned oncology professionals passionately dedicated to working to accelerate oncology drug development, improve treatment outcomes and extend lives. Our core platform, the Champions TumorGraft™ offers an enhanced xenograft mouse avatar.

www.championsoncology.com

Exhibitor

Repositive is a technology company with the mission to increase discovery, access and sharing of genomic data for the benefit of patients. In 2017 we initiated a collaboration with leading biopharma organisations and CROs to launch the Cancer Models Platform to act as a market place of translational oncology models and a network for oncology researchers. The platform incorporates PDX, CDX, syngeneic and humanised mouse models, 3D in vitro systems and other popular translational cancer models. Our vision is becoming the largest catalogue of commercially available oncology models.

www.repositive.io

Become Our PREDiCT Series Partner

Drop me a line to find out more

Diane McKenna
Commercial Director, Tumor Models
T: +44 203 1418746
E: sponsor@hansonwade.com

READY TO REGISTER?

3 EASY WAYS TO BOOK

www.tumour-models.com/register

Tel: +44 (0)203 141 8700

Email: register@hansonwade.com

Top 3 Reasons for Attending:

1. Optimise model selection & characterisation
2. Benchmark against leading pharmaceutical organisations
3. Explore model advances & drive translational decision making

Team Discounts*

- **10% discount – 3 delegates**
- **15% discount – 4 delegates**
- **20% discount – 5 or more delegates**

Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: register@hansonwade.com

SECURE YOUR PLACE

Model & Service Providers Pricing	Register & Pay before 23/8/2019 **Save up to £700**	Standard Price
Gold: Conference + 2 Workshops	£3,297	£3,797
Silver: Conference + 1 Workshop	£2,798	£3,298
Bronze: Conference Only	£2,299	£2,799
Workshops (Each)	£599	

Drug Developers Pricing	Register & Pay before 23/8/2019 **Save up to £700**	Standard Price
Gold: Conference + 2 Workshops	£2,497	£2,997
Silver: Conference + 1 Workshop	£2,098	£2,598
Bronze: Conference Only	£1,699	£2,199
Workshops (Each)	£599	

Academics are entitled to an exclusive discount, please contact info@hansonwade.com for further information.
Please note Prices do not include VAT



VENUE

DoubleTree By Hilton – Tower of London
7 Pepys Street, London
EC3N 4AF,United Kingdom

For further information or assistance, please visit www.doubletree3.hilton.com